| abstract |
The present invention provides a novel use of DPIV-inhibitors. The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, comprise conditions mediated by DPIV or DPIV-like enzymes, such as seizures, tumors, ischemia, Parkinson's disease and migraine Useful for the treatment of an immune, autoimmune or central nervous system disease selected from the group. In a more preferred embodiment, the compounds of the present invention are useful for treating multiple sclerosis. |